Effects of Melatonin And/or Magnesium Supplementation on Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial

Overview

Journal Biol Trace Elem Res

Date 2021 May 19

PMID 34009514

Citations 16

Authors

Reihaneh Mousavi

Mohammad Alizadeh

Mohammad Asghari Jafarabadi

Lida Heidari

Roshan Nikbakht

Hossein Babaahmadi Rezaei

Majid Karandish

Affiliations

Soon will be listed here.

Abstract

Magnesium and melatonin are known to exert multiple beneficial effects including anti-inflammatory and antioxidant actions. This study was designed to determine the effects of magnesium and/or melatonin supplementation on metabolic profiles in women with polycystic ovary syndrome (PCOS). This randomized double-blind, placebo-controlled trial was conducted among 84 subjects with PCOS aged 18-40 years old. Patients were randomly assigned based on the random block procedure to take magnesium, melatonin, magnesium plus melatonin, or placebo for 8 weeks. Fasting blood samples were taken at baseline and after the intervention to quantify related variables. After the 8-week intervention, an insignificant marginal difference was seen in waist circumference (WC) between groups (P = 0.085). Magnesium-melatonin co-supplementation resulted in more reductions in hirsutism compared with other groups (P < 0.001). Serum levels of tumor necrosis factor-α (TNF-α) declined significantly in the melatonin and co-supplementation groups compared to baseline (P < 0.05). Also, magnesium plus melatonin was associated with a more increase in total antioxidant capacity (TAC) levels, as compared to the other treatment groups (P = 0.001). Overall, we found a favorable effect of co-supplementation of magnesium and melatonin for 8 weeks in women with PCOS on hirsutism, serum TNF-α, and TAC levels. Furthermore, melatonin independently contributed to decreased serum values of TNF-α.Clinical trial registration number http://www.irct.ir : IRCT20191130045556N1, January 2020.

Citing Articles

Does Magnesium Affect Sex Hormones and Cardiometabolic Risk Factors in Patients with PCOS? Findings from a Systematic Review and Meta-Analysis.

Abu-Zaid A, Alzayed M, Albahrani S, Almaqhawi A, Al Shaikh M, Baradwan S Medicina (Kaunas). 2025; 61(2).

PMID: 40005397 PMC: 11857371. DOI: 10.3390/medicina61020280.

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

Melatonin, an Antitumor Necrosis Factor Therapy.

Alvarez-Lopez A, Cruz-Chamorro I, Lardone P, Bejarano I, Aspiazu-Hinostroza K, Ponce-Espana E J Pineal Res. 2024; 77(1):e70025.

PMID: 39740227 PMC: 11685806. DOI: 10.1111/jpi.70025.

Mental Health Across the Menstrual Cycle in Polycystic Ovary Syndrome: Insights and Implications.

Phimphasone-Brady P, Ross K, Zhang A, Sehrt M, McKenney K, Lebin L Curr Psychiatry Rep. 2024; 26(11):553-562.

PMID: 39214948 DOI: 10.1007/s11920-024-01529-w.

Magnesium: A Defense Line to Mitigate Inflammation and Oxidative Stress in Adipose Tissue.

Cazzola R, Porta M, Piuri G, Maier J Antioxidants (Basel). 2024; 13(8).

PMID: 39199139 PMC: 11351329. DOI: 10.3390/antiox13080893.

References

Glueck C, Papanna R, Wang P, Goldenberg N, Sieve-Smith L . Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003; 52(7):908-15. DOI: 10.1016/s0026-0495(03)00104-5. View

Artimani T, Karimi J, Mehdizadeh M, Yavangi M, Khanlarzadeh E, Ghorbani M . Evaluation of pro-oxidant-antioxidant balance (PAB) and its association with inflammatory cytokines in polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2017; 34(2):148-152. DOI: 10.1080/09513590.2017.1371691. View

Shorakae S, Teede H, de Courten B, Lambert G, Boyle J, Moran L . The Emerging Role of Chronic Low-Grade Inflammation in the Pathophysiology of Polycystic Ovary Syndrome. Semin Reprod Med. 2015; 33(4):257-69. DOI: 10.1055/s-0035-1556568. View

Repaci A, Gambineri A, Pasquali R . The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2010; 335(1):30-41. DOI: 10.1016/j.mce.2010.08.002. View

Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale H . Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013; 19(3):268-88. DOI: 10.1093/humupd/dms059. View

Chakraborty P, Ghosh S, Goswami S, Kabir S, Chakravarty B, Jana K . Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res. 2013; 152(1):9-15. DOI: 10.1007/s12011-012-9592-5. View

Zhang D, Luo W, Liao H, Wang C, Sun Y . [The effects of oxidative stress to PCOS]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008; 39(3):421-3. View

Cagnacci A, Volpe A . A role for melatonin in PCOS?. Fertil Steril. 2002; 77(5):1089; author reply 1089-90. DOI: 10.1016/s0015-0282(02)03070-4. View

Reiter R, Tan D, Fuentes-Broto L . Melatonin: a multitasking molecule. Prog Brain Res. 2010; 181:127-51. DOI: 10.1016/S0079-6123(08)81008-4. View

10.

Tan D, Manchester L, Sainz R, Mayo J, Leon J, Hardeland R . Interactions between melatonin and nicotinamide nucleotide: NADH preservation in cells and in cell-free systems by melatonin. J Pineal Res. 2005; 39(2):185-94. DOI: 10.1111/j.1600-079X.2005.00234.x. View

11.

Reiter R, Tan D, Maldonado M . Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res. 2005; 39(2):215-6. DOI: 10.1111/j.1600-079X.2005.00261.x. View

12.

Galano A, Tan D, Reiter R . Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011; 51(1):1-16. DOI: 10.1111/j.1600-079X.2011.00916.x. View

13.

Tamura H, Nakamura Y, Korkmaz A, Manchester L, Tan D, Sugino N . Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2008; 92(1):328-43. DOI: 10.1016/j.fertnstert.2008.05.016. View

14.

Pacchiarotti A, Carlomagno G, Antonini G, Pacchiarotti A . Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2015; 32(1):69-73. DOI: 10.3109/09513590.2015.1101444. View

15.

Glasdam S, Glasdam S, Peters G . The Importance of Magnesium in the Human Body: A Systematic Literature Review. Adv Clin Chem. 2016; 73:169-93. DOI: 10.1016/bs.acc.2015.10.002. View

16.

Asemi Z, Esmaillzadeh A . DASH diet, insulin resistance, and serum hs-CRP in polycystic ovary syndrome: a randomized controlled clinical trial. Horm Metab Res. 2014; 47(3):232-8. DOI: 10.1055/s-0034-1376990. View

17.

Szczuko M, Skowronek M, Zapalowska-Chwyc M, Starczewski A . Quantitative assessment of nutrition in patients with polycystic ovary syndrome (PCOS). Rocz Panstw Zakl Hig. 2016; 67(4):419-426. View

18.

Hamilton K, Zelig R, Parker A, Haggag A . Insulin Resistance and Serum Magnesium Concentrations among Women with Polycystic Ovary Syndrome. Curr Dev Nutr. 2019; 3(11):nzz108. PMC: 6822014. DOI: 10.1093/cdn/nzz108. View

19.

Maktabi M, Jamilian M, Asemi Z . Magnesium-Zinc-Calcium-Vitamin D Co-supplementation Improves Hormonal Profiles, Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2017; 182(1):21-28. DOI: 10.1007/s12011-017-1085-0. View

20.

Moslehi N, Vafa M, Rahimi-Foroushani A, Golestan B . Effects of oral magnesium supplementation on inflammatory markers in middle-aged overweight women. J Res Med Sci. 2013; 17(7):607-14. PMC: 3685774. View